MedTrace Logo

Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants

NCT00143312 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2009-10-06

Study results available
· View outcomes & findings →

Summary

To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants

Conditions

  • Prophylaxis Of Invasive Fungal Infections

Interventions

DRUG

voriconazole

Voriconazole is given to patients at least 48 hours after chemotherapy

Sponsors & Collaborators

  • European Society for Blood and Marrow Transplantation

    collaborator NETWORK

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Belgium
  • France
  • Germany
  • Portugal
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143312 on ClinicalTrials.gov